946774-77-2

Upstream product

• 364-74-9 1,4-difluoro-2-nitrobenzene 
• 394-33-2 2-nitro-4-fluorophenol 
• 1092496-26-8 4-fluoro-2-nitro-1-propoxybenzene 

Downstream Products

• 1092496-70-2 2,2,2-trifluoro-N-(5-fluoro-2-propoxyphenyl)acetamide 
• 1092496-61-1 5-[(5-fluoro-2-propoxyphenylamino)methylene]-2,2-dimethyl-[1,3]dioxane-4,6-dione 
• 1092495-21-0 5-fluoro-3-(4-methoxyphenyl)-8-propoxy-1H-quinolin-4-one 
• 1092496-06-4 5-fluoro-3-(4-methoxyphenyl)-1-methyl-8-propoxy-1H-quinolin-4-one 
• 1092496-10-0 5-fluoro-3-(4-hydroxyphenyl)-8-propoxy-1H-quinolin-4-one 
• 1092496-71-3 4,4,4-trifluoro-3-(5-fluoro-2-propoxyphenylamino)buta-2-enoic acid ethyl ester 

Relevant academic research and scientific papers

METHOD FOR PRODUCING QUINOLONE COMPOUND OR SALT THEREOF

PROBLEM TO BE SOLVED: To provide a method for producing 5-fluoro-3-(4-methoxyphenyl)-8-propoxy-1H-quinolin-4-one and a salt thereof industrially advantageously, the compound being known as one which suppresses progression of nervous function disorder and has a function improving effect. SOLUTION: Provided is a method for producing 5-fluoro-3-(4-methoxyphenyl)-8-propoxy-1H-quinolin-4-one and a salt thereof, comprising a step of reacting ethyl α-(hydroxymethylene)-4-methoxyphenylacetate and a salt, especially a sulfate salt, of 5-fluoro-2-propoxyaniline. SELECTED DRAWING: None COPYRIGHT: (C)2018,JPOandINPIT

QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION

The present invention provides a quinolone compound represented by General Formula (1) or a salt thereof, wherein R1 represents a hydrogen atom, etc.; R2 represents a hydrogen atom, etc.; R3 represents a phenyl group optio